Protelix, Inc. is aiming to build upon their extensive patented technology and the latest advances in evolutionary mutagenesis to address critical medical needs. The principal focus is to develop superior next generation protein based therapeutics including cytokines, enzymes and novel human biotherapeutic vaccine candidates. Protelix´s technology platform is based on Dr. Roberto Crea´s Walk-Through Mutagesis and Look-Through-Mutagenesis that accelerates protein evolution. Perform targeted site directed mutagenesis that systematically maps the most important residues for inclusion in combinatorial mutagenesis and isolation of the best candidates. Able to generate and screen diverse libraries of high information and sequence space by integrating bioinformatics knowledge database of structure/function relationships, computational homology and biological relevanc
